Stopping Metoprolol: What Withdrawal and Post-MI Studies Show
Stopping metoprolol raises two separate questions: does it still offer useful long-term treatment, and how can it be withdrawn safely? A decision that treatment may no longer be needed does not establish that stopping abruptly is safe. The tartrate label warns about worsening angina and reported heart attacks after abrupt withdrawal of chronic treatment. The succinate product carries the same warning.[1][2]
What the withdrawal instructions mean
Both labels advise gradual reduction over 1–2 weeks with monitoring, particularly in people with ischemic heart disease. The labels do not specify one milligram-by-milligram schedule for every patient. The succinate label also cautions against abrupt withdrawal when treating hypertension alone, because coronary disease may be unrecognized.[1][2]
The formulations have different release profiles and should not be treated as interchangeable schedules. Identify the actual product before discussing any change. The succinate label calls for prompt treatment if angina markedly worsens or acute coronary ischemia develops during withdrawal.[1]
What the modern post-heart-attack trials tested
The 2023 chronic coronary disease guideline allows reassessment of beta-blocker treatment beyond one year after a heart attack in selected people without a history of or current ejection fraction at or below 50%, angina, arrhythmias, or uncontrolled hypertension. It does not recommend that everyone with a previous heart attack stop treatment.[3]
ABYSS and SMART-DECISION subsequently tested treatment interruption in selected, stable patients. Their different primary endpoints matter when interpreting their results.[4][5]
| Feature | ABYSS | SMART-DECISION |
|---|---|---|
| Design and population | Open-label randomized trial; 3,698 stable patients in France with previous MI, LVEF ≥40%, and no cardiovascular event in the preceding six months | Open-label randomized trial; 2,540 patients at 25 South Korean centers, with previous MI, at least one year of beta-blocker treatment, LVEF ≥40%, and no heart failure |
| Primary endpoint | Death, nonfatal MI, nonfatal stroke, or hospitalization for cardiovascular reasons | All-cause death, recurrent MI, or hospitalization for heart failure |
| Follow-up and result | Median 3.0 years; interruption did not demonstrate noninferiority, and quality of life did not improve | Median 3.1 years; discontinuation met the trial’s noninferiority criterion: hazard ratio 0.80, 95% CI 0.57–1.13, with an upper margin of 1.4 |
| Sources | [4] | [5] |
ABYSS counted a broader range of cardiovascular hospitalizations; SMART-DECISION specifically counted heart-failure hospitalization alongside death and recurrent MI. Their conclusions therefore address different composite outcomes. Neither trial establishes that unsupervised abrupt stopping is safe, and neither supplies a universal metoprolol taper. A trial's noninferiority result applies to its chosen endpoint and margin.[4][5]
Heart failure changes the discussion
For heart failure with reduced ejection fraction, sustained-release metoprolol succinate is one of three beta-blockers recommended to reduce mortality and hospitalizations. The heart-failure guideline cautions that abrupt withdrawal can cause clinical deterioration.[6]
OPTIMIZE-HF provides a different kind of evidence: in an observational registry of hospitalized patients with systolic heart failure, withdrawal was associated with higher adjusted mortality than continuation. Illness severity and treatment selection may have influenced that association. It is not a causal estimate of an otherwise stable outpatient’s personal stopping risk.[7]
Why withdrawal has no universal clock
A small historical study of eight people with hypertension found increased resting heart rate and beta-adrenergic sensitivity 2–8 days after abrupt withdrawal. A separate post-MI study found heart-rate rebound over three weeks despite a one-week withdrawal period. These studies show that rebound can occur, including after gradual reduction; they cannot predict an individual symptom countdown.[8][9]
For the next medication review, make a short record: why metoprolol was prescribed; the actual product, strength, and schedule; recent missed doses or symptoms; and treatment duration. Ask whether the original indication remains, what stopping would aim to achieve, and what monitoring the plan requires.
Frequently asked questions
Can I stop 25 mg of metoprolol suddenly?
A tablet strength does not resolve the reason for treatment, duration or formulation. Both labels advise against interrupting chronic treatment without prescriber advice.[1][2] Bring the actual prescription to review rather than treating a low strength as permission to stop.
What is the safest metoprolol taper schedule?
Both labels describe gradual reduction over one to two weeks with monitoring.[1][2] The actual dose steps depend on the prescription and clinical situation. Ask for a written plan that specifies the steps, the review arrangements and what to do if symptoms change.
How long does metoprolol withdrawal last?
The small historical studies observed rebound over days to weeks; they do not supply a personal countdown.[8][9] Worsening angina or possible acute ischemia requires prompt assessment during withdrawal.[1] Record when the prescription changed and when symptoms began.
Is it safe to stop metoprolol if my blood pressure is normal?
Normal blood pressure alone does not show that treatment is unnecessary. Metoprolol may also be treating angina, an arrhythmia, or heart failure. Review the original indication and current heart function before deciding whether long-term treatment should continue.[3][6]
Should I double metoprolol after a missed dose?
No. The tartrate label says to take only the next scheduled dose without doubling; the succinate label gives the same instruction.[1][2] Describe a longer gap or new symptoms to the pharmacist or prescriber rather than designing a catch-up schedule.
Can metoprolol be stopped years after a heart attack?
Sometimes treatment can be reassessed, depending on heart function and other indications. ABYSS did not establish noninferiority of interruption; SMART-DECISION did, using a different primary endpoint. Neither result means everyone should stop or that abrupt withdrawal is safe.[3][4][5]
References
Sources checked October 14, 2026.
- Metoprolol succinate extended-release tablets: prescribing information. DailyMed.
- Metoprolol tartrate tablets: prescribing information. DailyMed.
- 2023 AHA/ACC multisociety guideline for the management of patients with chronic coronary disease.
- Silvain J, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction: ABYSS. 2024.
- Choi KH, et al. SMART-DECISION: beta-blocker discontinuation after myocardial infarction. 2026.
- 2022 AHA/ACC/HFSA guideline for the management of heart failure.
- Fonarow GC, et al. Beta-blocker continuation or withdrawal in hospitalized heart failure: OPTIMIZE-HF. 2008.
- Rangno RE, et al. Metoprolol withdrawal phenomena: mechanism and prevention. 1982.
- Olsson G, et al. Rebound phenomena following gradual withdrawal of chronic metoprolol treatment after myocardial infarction. 1984.
